OHF

Oxalosis & Hyperoxaluria Foundation

Detailed Workshop Agenda

DOWNLOAD IHW 2026 AGENDA IN .PDF
IHW 2026 Workshop Schedule
Start Name Affiliation Country Title
Friday, 26 June 2026
8:00 AM Registration
8:45 AM Jakub Zieg, MD, PhD University Hospital Motol, Prague Czech Republic Welcome
8:50 AM Kyle Wood, MD & Yaacov Frishberg, MD University of Alabama, Birmingham & Shaare Zedek Medical Center United States & Israel Introduction
9:00 AM Peter C. Harris, PhD Mayo Clinic, Rochester United States Is There Further Genetic Heterogeneity in PH? Lessons from Polycystic Kidney Disease
Session 1: From Metabolism to Disease: The Impact of Oxalate
Chair: Todd Lowther, PhD
Wake Forest University School of Medicine
United States
9:25 AM Ehud Ohana, PhD Ben Gurion University of the Negev Israel Altered Metabolic Homeostasis Rewires Hepato-Renal Axis Signaling in Primary Hyperoxaluria Type 3
9:40 AM Gerlineke Hawkins Van der Cingel, MBBS Charité – Universitätsmedizin Berlin Germany Effect of Lumasiran in Hyperoxalaemic Patients on Maintenance Haemodialysis
9:55 AM Kyle Wood, MD University of Alabama, Birmingham United States Mouse model of MASH
Oral Abstract Speed Round:
10:10 AM Sonia Fargue, MD, PhD University of Alabama, Birmingham United States Metabolic Dysfunction-Associated Steatotic Liver Disease in a Mouse Model of Primary Hyperoxaluria Type 1
10:17 AM Coffee Break
Session 2: From Bench to Bedside: PH2 and PH3
Chair: Hadas Shasha-Lavsky, MD
Galilee Medical Center
Israel
10:45 AM Efrat Ben-Shalom, MD Shaare Zedek Medical Center Israel What Have We Learned Since the Discovery of PH3?
11:00 AM Nicola Brunetti-Pierri, MD University of Naples Italy Animal Models for PH3
11:15 AM Ruth Belostotsky, PhD Shaare Zedek Medical Center Israel Primary Hyperoxaluria Type 3 Metabolites: Are They Drivers of the Disease?
11:30 AM Tijn Rozemuller, MD, PhD Amsterdam University Medical Center The Netherlands Why Did Nedosiran Not Work in PH2/PH3?
11:45 AM Moderator: Michael Somers, MD Boston Children's Hospital United States Panel: All session speakers
12:00 PM Lunch Break
Session 3: Where We Are Today: Treatment of Primary Hyperoxaluria
Chair: Mathieu Lemaire, MSc MDCM PhD FRCP(C)
The Hospital for Sick Children Toronto
Canada
1:00 PM David Sas, DO Mayo Clinic, Rochester United States Real World Use of siRNA
1:15 PM Mathieu Lemaire, MD MSc MDCM PhD FRCP(C) The Hospital for Sick Children Toronto Canada Move Over, Liver Kidney-Alone Transplantation Takes Center Stage for PH1 - Thanks to siRNA Therapy
1:30 PM Laila Oubram, MD Amsterdam University Medical Center Netherlands Optimizing Access to Lumasiran in Primary Hyperoxaluria Type 1 through a National Response-Guided Protocol
1:37 PM Kyle Wood, MD University of Alabama, Birmingham United States Medical vs. Surgical: Where Do New Therapies Change the Game?
Oral Abstract Speed Round:
1:52 PM Hadas Shasha - Lavsky, MD Galilee Medical Center Israel Israel Lumasiran Treatment Outcomes in Infants with Primary Hyperoxaluria Type 1
1:59 PM Laila Oubram, MD Amsterdam University Medical Center Netherlands Pregnancy During Active Lumasiran Therapy in Primary Hyperoxaluria Type 1
2:06 PM Georgia Mandrile, MD, PhD AOU San Luigi Gonzaga Italy Functional and In Silico Characterization of Common AGXT Variants as Potential Modifiers of Primary Hyperoxaluria Type 1
2:13 PM Moderator: Michelle Baum, MD Boston Children's Hospital United States Panel: All session speakers
2:30 PM Coffee Break
Session 4: Managing Stone Burden: Urological Perspectives in Hyperoxaluria
Chair(s): Thomas Chi, MD, MBA, FACS & Zham Okhunov, M.D.
The University of Alabama, Birmingham & University of Utah
United States
3:00 PM Tom Chi, MD, MBA, FACS University of Alabama, Birmingham United States Bridging the Gap: Urologys Role in Early Detection of Hyperoxaluria
3:15 PM Kevin Koo, MD Mayo Clinic, Rochester United States What Are Endourologists Thinking? The Surgical Perspective on Complex Stones
3:30 PM Chen-Han Wilfred Wu, MD, PhD University of Alabama Birmingham United States The Perspective of a Geneticist: Rare Stone Disease
Oral Abstract Speed Round:
3:45 PM Mazzy Marcucci, BS University of Utah United States Data-Driven Metabolic Phenotyping of Calcium Oxalate Nephrolithiasis Using Model-Based Clustering
3:52 PM Qazi Saqib Hamid, MD Aga Khan University Pakistan Contribution of Primary Hyperoxaluria in a High-Risk Pakistani Cohort: Genetic and Phenotypic Insights
3:59 PM Moderator(s): Kyle Wood, MD University of Alabama Medicine, Birmingham United States Audience Polling & Panelists: All session speakers
4:15 PM Kyle Wood, MD University of Alabama Medicine, Birmingham United States Day 1 Closing
4:20 PM Welcome Reception / Poster Session
5:20 PM FINISH
Saturday, 27 June 2026
8:00 AM Registration & Poster Viewing
8:45 AM Kim Hollander Oxalosis and Hyperoxaluria Foundation United States Day 2 Welcome
Session 5: Enteric Hyperoxaluria: What’s Next in Care and Treatment
Chair(s): Jonathan Whittamore, PhD & Dirk Lange, PhD
UT Southwestern Medical Center & University of British Columbia
United States & Canada
8:50 AM Elaine Worcester, MD University of Chicago Medicine United States Outcomes of Enteric Hyperoxaluria – Stone and CKD Risk
9:05 AM John Knight, PhD University of Alabama, Birmingham United States Enteric Hyperoxaluria: The Role of Oxalobacter Formigenes or Other Genetically Modified Bacteria
9:20 AM Lama Nazzal, MD NYU Langone Health United States Targeting the Oxalobiome: Therapeutic Opportunities and Translational Challenges
9:35 AM Abraham Matar, MD Dartmouth Geisel School of Medicine United States From Bariatric Surgery to Enteric Hyperoxaluria and Kidney Transplantation
9:50 AM John Lieske, MD Mayo Clinic, Rochester United States What Happened to Enteric Hyperoxaluria Therapies?
10:05 AM Coffee Break
Session 6: Pipeline and Progress: Emerging Therapies in Primary Hyperoxaluria
Chair(s): Sonia Fargue, MD, PhD & Monica Diaz Gavilan, PhD
University of Alabama, Birmingham & University of Granada
United States & Spain
10:30 AM Monica Diaz Gavilan, PhD University of Granada Spain Small Molecules– Targeting Protein Degradation in PH1
10:45 AM Barbara Cellini, PhD University of Perugia Italy Misfolding-Corrective Approaches in the Therapy of PH1
11:00 AM Mervi E. Hyvönen, MD, PhD Helsinki University Hospital and University of Helsinki Finland Gene Editing as a Therapeutic Strategy for Hyperoxaluria
11:15 AM Michelle Logsdon Gauvin, PhD Stanford University United States Potential for mRNA Therapeutics in Primary Hyperoxaluria
11:30 AM Emmanuel Letavernier, MD, PhD Tenun Hospital France Stiripentol: Set-up of the CRYSTAL Study
11:40 AM Marc De Broe, MD, PhD Antwerp University Hospital Belgium The Role of the Gut for PH Treatment
11:55 AM John Lieske, MD Mayo Clinic, Rochester United States redePHine: Advancing Gene Editing for Primary Hyperoxaluria Type 1
12:05 PM Matthew Breeggemann, MD University of California San Francisco United States YOLT-203, an In Vivo Gene-Editing Therapy for Primary Hyperoxaluria Type 1: Interim Results from Two Investigator-Initiated Trials
Oral Abstract Speed Round:
12:15 PM Todd Lowther, PhD Wake Forest University School of Medicine United States Inhibition of Hydroxyproline Dehydrogenase as a Therapy for Primary Hyperoxaluria
12:22 PM Lisa Ellerby, PhD The Buck Institute United States N-Propargylglycine Restores Survival by Preventing Calcium Oxalate Stone Formation, Tubular Injury, and Kidney Dysfunction in a Lethal Mouse Model of Primary Hyperoxaluria Type 2
12:30 PM Lunch Break
Session 7: From Data to Care: Registries & Centers of Excellence
Chair: Shabbir Moochhala, MD, PhD, FRCPE
Royal Free Hospital
United Kingdom
1:30 PM Kim Hollander, Executive Director The Oxalosis and Hyperoxaluria Foundation United States Advancing Hyperoxaluria Through Global Collaboration Subtitle: Partnering with Patients, Clinicians, Researchers, and Advocates Worldwide
1:40 PM Bhaskar Somani, MD University Hospital Southampton NHS Trust United Kingdom How to Create a Multidisciplinary Stone Teams
1:55 PM Matthew Breeggemann, MD University of California San Francisco United States OHF Care Center Network: Advancing Global Care Together
2:10 PM Shabbir Moochhala, MD, PhD, FRCPE & John Lieske, MD Royal Free Hospital & Mayo Clinic, Rochester United States & United Kingdom PH Registries: Collaboration in Action
Living with Hyperoxaluria: Global Patient and Caregiver Perspectives on Care, Access, and Treatment
Moderator: Kevin Koo, MD
Mayo Clinic
United States
2:25 PM Luigi (Italy) - Italian Hyperoxaluria Association
Kristi (United States) - Finding A Way
Maarten (the Netherlands)
Zain (United Kingdom)
Irene (Poland) - PH-Europe
2:50 PM Coffee Break
Session 8: Global Perspectives in PH: Insights from Around the World
Chair(s): Mini Michael, MD & Yaacov Frishberg, MD
3:20 PM Velibor Tasic, MD, PhD, FESPN University Children's Hospital Macedonia
3:27 PM Eva Flachsova, MD, PhD Charles University Czech Republic
3:34 PM Naveen Soliman, MD Cairo University Egypt
3:41 PM Faïza Meiouet, PhD Royal Gendarmerie Medical Research and Analysis Laboratory Morocco
3:48 PM Marta Monteverde, MD Hospital de Pediatría JP Garrahan Argentina
3:55 PM Maria Helena Vaisbich, MD, PhD University of São Paulo School of Medicine – Clinics Hospital Brazil
4:02 PM Aditi Sinha, MD, PhD All India Institute of Medical Sciences India
4:09 PM Seema Hashmi, MD Sindh Institute of Urology and Transplantation Pakistan
4:16 PM Moderator(s): Mini Michael, MD & Yaacov Frishberg, MD Texas Children's Hospital & Shaare Zedek Medical Center United States & Israel Panel: All Speakers
4:30 PM Kyle Wood, MD and Yaacov Frishberg, MD University of Alabama, Birmingham & Shaare Zedek Medical Center United States & Israel Closing
4:35 PM FINISH
7:00 PM Trolley Transfer to Farewell Dinner
Farewell Dinner